Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
32.94 CHF | +0.52% |
|
+3.65% | +21.73% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
May. 22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+21.73% | 15.93B | |
+16.80% | 43.26B | |
+17.47% | 21.6B | |
+23.95% | 15.1B | |
+57.96% | 12.95B | |
-0.05% | 6.79B | |
-16.22% | 6.29B | |
+19.77% | 6.04B | |
-8.87% | 5.73B | |
+25.45% | 4.64B |
- Stock Market
- Equities
- SDZ Stock
- News Sandoz Group AG
- Stifel Initiates Sandoz with Buy Rating